Ming Kand Pharmaceuticals announced that it will hold its second Class H Shareholders' Meeting 2024 on 12 June 2024 at the Sheraton Shanghai Takahashi Hotel in the Shanghai Free Trade Pilot Zone, Shanghai, China. THE MEETING WILL CONSIDER GENERAL AUTHORISATION RESOLUTIONS TO REPURCHASE A SHARES AND/OR H SHARES AND SHALL BE IMPLEMENTED IN ACCORDANCE WITH CHINESE LAWS, REGULATIONS AND REGULATIONS AND SUBJECT TO THE APPROVAL OF RELEVANT REGULATORY AUTHORITIES. The total value of the shares repurchased must not exceed 10% of the issued shares and must be approved by a special resolution of the General Meeting. In addition, the meeting will authorize the Board to develop and implement the repurchase plan, including the repurchase price, quantity and term. The registration of shareholders will be suspended from 5 to 12 June 2024 to determine eligibility to attend the general meeting and vote. THE COMPANY ENCOURAGES SHAREHOLDERS TO APPOINT THE CHAIRMAN OF THE GENERAL MEETING AS A REPRESENTATIVE FOR VOTING.

Ming Kand Pharmaceuticals announced that it will hold its second Class H Shareholders' Meeting 2024 on 12 June 2024 at the Sheraton Shanghai Takahashi Hotel in the Shanghai Free Trade Pilot Zone, Shanghai, China. THE MEETING WILL CONSIDER GENERAL AUTHORISATION RESOLUTIONS TO REPURCHASE A SHARES AND/OR H SHARES AND SHALL BE IMPLEMENTED IN ACCORDANCE WITH CHINESE LAWS, REGULATIONS AND REGULATIONS AND SUBJECT TO THE APPROVAL OF RELEVANT REGULATORY AUTHORITIES. The total value of the shares repurchased must not exceed 10% of the issued shares and must be approved by a special resolution of the General Meeting. In addition, the meeting will authorize the Board to develop and implement the repurchase plan, including the repurchase price, quantity and term. The registration of shareholders will be suspended from 5 to 12 June 2024 to determine eligibility to attend the general meeting and vote. THE COMPANY ENCOURAGES SHAREHOLDERS TO APPOINT THE CHAIRMAN OF THE GENERAL MEETING AS A REPRESENTATIVE FOR VOTING.